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Purpose: To evaluate the safety and efficacy of hylan G-F 20
viscosupplementation in patients with symptomatic osteoarthritis
(OA) of the ankle.
Methods: Prospective, multi-center, open study in patients with
primary or secondary grade II talocrural OA confirmed by X-ray.
At baseline, patients had to score between 50-90 mm on the
Patient-completed Ankle OA Pain VAS (0 -100 mm). Patients
received one intra-articular injection of 2 ml of hylan G-F 20 and
were given an option of a second and final 2 ml injection if their
pain remained between 50-90 mm on the VAS after 1, 2 or 3
months. Intra-articular injections were placed in the anteromedial
portal of the ankle joint as described for ankle arthroscopy.
Patients were followed for 6 months after the final injection. As
rescue medication, patients could only take paracetamol up to 4
g per day, except on the day of or the day before a study visit.All
treatment emergent adverse events (AEs) were recorded. The
primary efficacy endpoint was change from baseline (at final
injection) in the Ankle OA Pain VAS at 3 months after the final
injection. Secondary endpoints were Ankle OA Pain VAS scores
at all other time-points, total Ankle OA Scale, Patient’s and
Physician’s Global OA Assessment (VAS), and health-related
quality of life (SF-36).
Results: Fifty-five patients (33 M; 22 F) were enrolled and re-
ceived a first injection of hylan G-F 20. Twenty-four patients
(44%) received a second injection. The mean age was 41 years
(range 19-70). Overall, treatment with hylan G-F 20 was well
tolerated. Seventeen patients (31%) had a treatment related AE
of the target ankle. All were of mild or moderate intensity, the ma-
jority consisting of arthralgia and injection site pain. There was
a statistically significant decrease in Ankle OA Pain VAS score
from 68.0 mm at Baseline to 33.8 mm at Month 3 (p<0.001,
paired t-test), which was maintained at 6 months follow-up. The
decrease was statistically significant at all time points. Patients
who received only 1 injection demonstrated a greater decrease at
3 months (-42.5 mm) than patients with 2 injections (-23.5 mm).
The secondary efficacy endpoints showed similar results. Of the
total study population, 29 patients (53%) were responders (i.e.
at least a 50% decrease in ankle OA pain) after 3 months. 64%
of patients receiving 1 injection were responders after 3 months.
The SF-36 questionnaire showed statistically significant improve-
ments for both the physical and mental component scores at 3
and 6 months follow-up.
Conclusions: Treatment of OA of the ankle with intra-articular
hylan G-F 20 injections is well tolerated. Treatment with hylan
G-F 20 significantly decreases pain which is maintained for up to
6 months.
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Purpose: Hip osteoarthritis (OA) is a very frequent disease
representing the most prevalent joint disorder in adults older than
50 years. Acetaminophen is considered a first-line treatment,
but its efficacy is weak and frequently unsatisfactory. NSAIDs
are the most common treatment to decrease pain and improve
function, but their use in the elderly is limited by possible serious
adverse events. Intra-articular use of hyaluronic acid has been
recently proposed as an alternative treatment for hip OA. To
date different treatment schedules have been proposed, but the
optimal regimen has not been established. We evaluated the
efficacy and safety of a two ultrasound (US)-guided injection
course of Hylan G-F 20 for hip OA.
Methods: Thirty-six patients affected by symptomatic hip OA
(24 F and 12 M; age 43-84 years; 10 had grade 1, 9 grade
2, 15 grade 3 and 2 grade 4 hip OA) were treated with a
two-intraarticular injection course of Hylan G-F 20 two weeks
apart. The injections were performed under US guidance with
an antero-superior approach. Patients were followed for a 6-
month period. Treatment efficacy was assessed through visual
analogue scale (VAS) pain quantification (baseline, 2 weeks
and 6 months), acetaminophen/NSAIDs intake (baseline and 6
months), Lequesne index (baseline and 6 months), and WOMAC
Osteoarthritis Index (baseline and 6 months). Side effect was
recorded.
Results: VAS (2 weeks vs baseline, p<0.001; 6 months vs
baseline, p<0.0001), Lequesne index (6 months vs baseline,
p<0.0001), WOMAC (6 months vs baseline, p=0.001), and ac-
etaminophen/NSAIDs intake (6 months vs baseline, p=0.03) were
significantly reduced. Minor side effects were observed in 2 pa-
tients (mild pain in injection site after the first injection).
Conclusions: Viscosupplementation with is Hylan G-F 20 may
to represent a safe and efficacious approach for hip OA and our
schedule based on a two-intraarticular injection course every-
other week seems to supply pain relieve and functional improve-
ment lasting as long as 6 months with negligible side-effects.
Further studies are needed to determine the long-term efficacy
and the optimal treatment schedule.
Osteoarthritis Clinical Aspects
P322
ERAW
P. Chaturvedi1, L. Ramamurthy2, F. Wang1, C. Hanning1,
T. Burke3, J. Feild1, H. Fenderson1, S. Kumar1
1GSK, Collegeville, PA, 2GSK, RTP, NC, 3Duke University, RTP,
NC
Purpose: To evaluate the role of Rev-ErbAα in the regulation of
cartilage matrix genes including Col2A and SOX-9.
Methods: The search for DR2 elements on promoters of several
cartilage relevant genes was performed in-silico by bioinformatics
tools, NUBIScan and FindPatterns. To confirm the presence of
DR2 elements on promoters of SOX9 and Col2A, DR2 containing
regions of these promoters were amplified and cloned from ge-
nomic DNA. The binding of Rev-ErbAα to the promoters of these
genes was confirmed by Chromatin -Immunopreciptation (ChIP)
in C20/A4 cells. The effect of Rev-ErbAα on trans-repression of
SOX-9 and Col2A was also evaluated by real time- quantitative
PCR and a reporter assay, respectively.
